PROVIDER*Update*

CONTRACTUAL

NOVEMBER 26, 2019

UPDATE 19-927

Injectable Medication HCPCS/DOFR Crosswalk Reference Table Update – 4th Quarter 2019

Approved updates are effective February 3, 2020

On October 15, 2019, the Health Net* Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates are effective February 3, 2020, and listed on pages 2 and 3. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net *Provider Participation Agreement (PPA)*.


The update includes:

- Seven new injectable medications and DOFR categories.
- Updates and changes to 14 injectable medication procedure codes.
- One update to a category change.

Additional information

Relevant sections of Health Net's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library, located on Health Net's provider website as listed in the right-hand column.

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center by email at provider_services@healthnet.com within 60 days, by telephone or through the Health Net provider website as listed in the right-hand column.



THIS UPDATE APPLIES TO **CALIFORNIA** PROVIDERS:

O Physicians

3 PAGES

- Participating Physician Groups
- Hospitals
- O Ancillary Providers
- LINES OF BUSINESS:
- HMO/POS/HSP
- ° EPO
- Medicare Advantage (HMO)
- Medi-Cal
 - Kern
 - Los Angeles
 Molina
 - Riverside
 - Sacramento
 - San Bernardino
 - San Diego
 - San Joaquin
 - Stanislaus
 - Tulare

PROVIDER SERVICES

provider_services@healthnet.com

Health Net Employer Group HMO, POS & HSP

1-800-641-7761

provider.healthnet.com

IFP – CommunityCare HMO & PureCare HSP

1-888-926-2164

provider.healthnetcalifornia.com Medicare (individual)

1-800-929-9224

provider.healthnetcalifornia.com Medicare (employer group)

1-800-929-9224 provider.healthnet.com **Medi-Cal** – 1-800-675-6110 provider.healthnet.com

PROVIDER COMMUNICATIONS provider.communications@ healthnet.com

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved by the Health Net P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from Health Net participating physician groups (PPGs).

| HCPCS | Drug name | Generic name | Primary category | Secondary category |
|-------|-----------------------------------|---|------------------|--------------------|
| Q5117 | Kanjinti [™] | Trastuzumab-anns,10 mg | Therapeutic inj | Chemotherapy* |
| J3490 | Vyleesi™ | Bremelanotide for subcutaneous use | Self-injectable | |
| J2794 | Ripererdal Consta [®] | Risperidone 0.5 mg, Injection | Therapeutic inj | |
| J7331 | Sodium Hyaluronate 1% | Sodium hyaluronate 1% for intra-articular injection | Therapeutic inj | |
| Q5116 | Trazimera™ | Trastuzumab-qyyp, 10 mg | Therapeutic inj | Chemotherapy* |
| J7314 | Yutiq [™] | Fluocinolone acetonide, intravitreal implant, 0.01 mg | Therapeutic inj | |
| Q5118 | Zirabev™ | Bevacizumab-bvzr,10 mg | Therapeutic inj | Chemotherapy* |

Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

| HCPCS | Drug name | Generic name | Comment |
|-------|---------------------------------|---|----------------|
| J3031 | Ajovy® | Fremanezumab-VFR | Replaces J3590 |
| J1943 | Aristada Initio [®] | Aripiprazole lauroxil extended-release injectable suspension | Replaces C9035 |
| J9269 | Elzonris® | Tagraxofusp-erzs injection, for intravenous use | Replaces C9049 |
| J9210 | Gamifant® | Emapalumab-Izsg injection, for intravenous use | Replaces C9050 |
| J9119 | Libtayo® | Cemiplimab-Rwlc IV solution | Replaces C9044 |
| J9313 | Lumoxiti [™] | Moxetumomab pasudotox-tdfk for injection, for intravenous use | Replaces C9045 |
| J0121 | Nuzyra® | Omadacycline for injection | Replaces C9051 |
| J0222 | Onpattro® | Patisiran lipid complex injection, for intravenous use | Replaces C9036 |
| J1096 | Ozurdex® | Dexamethasone intravitreal implant | Replaces C9048 |
| S1090 | Propel® | Mometasone furoate sinus implant, 370 micrograms | Discontinued |
| J2798 | Perseris™ | Risperidone for extended-release injectable suspension | Replaces C9037 |

Updates, continued

| HCPCS | Drug name | Generic name | Comment |
|-------|------------|---|----------------|
| J9204 | Poteligeo® | Mogamulizumab-kpkc injection, for intravenous use | Replaces C9038 |
| J1303 | Ultomiris™ | Ravulizumab-cwvz injection, for intravenous use | Replaces C9052 |
| J0291 | Zemdri™ | Plazomicin injection, for intravenous use | Replaces C9039 |

Category changes to HCPCS crosswalk

Secondary category additions were made to the HCPCS crosswalk for the following existing injectable medication.

| HCPCS | Drug name | Generic name | Primary category | Secondary category |
|-------|----------------------|--------------|------------------|----------------------|
| J2786 | Cinqair [®] | Reslizumab | Therapeutic inj | Home health/infusion |

*HCPCS codes were taken from the Centers for Medicare & Medicaid Services (CMS) HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.